Physician profile
Megan Joesting
NPI 1366895351
$2,841.91
in general payments reported to CMS, 2019-2025
23 companies · $755 in 2025
The $755 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $289 · 2023: $561 · 2024: $820 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.38 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $519.55 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $393.48 | 2021-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $267.88 | 2021-2025 | |
| Genzyme Corporation | $249.62 | 2023-2025 | |
| Abbvie INC. | $175.61 | 2022-2025 | |
| Galderma Laboratories, L.P. | $158.23 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Pfizer INC. | $137.87 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $106.33 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.52 | 2023-2025 | Sotyktu |
| Almirall LLC | $80.88 | 2021-2023 | Seysara |
| Amgen INC. | $74.74 | 2022-2025 | Otezla |
| Vyne Pharmaceuticals INC. | $68.91 | 2021 | |
| Dermavant Sciences, INC. | $65.28 | 2023-2024 | Vtama |
| Ucb, INC. | $61.90 | 2021-2024 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $56.36 | 2024 | Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.93 | 2023-2024 | Arazlo |
| Kerecis Limited | $39.98 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Leo Pharma INC. | $37.65 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $34.04 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $30.99 | 2021-2022 | |
| Organon LLC | $23.41 | 2025 | Vtama |
| Kyowa Kirin, INC. | $17.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Joesting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.